Drug Trial Radar · NCT01932970
Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide
Last checked: Nov 20, 2026Latest source record: Oct 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
158
Actual
Start
Aug 12, 2013
Primary completion
Jan 14, 2014
Study completion Feb 14, 2017
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Aug 30, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, multiple-dose, single-arm, open-label study to assess the impact on serum corrected calcium levels when switching patients from cinacalcet to etelcalcetide (AMG 416).
Conditions
- Hyperparathyroidism, Secondary
Interventions
EtelcalcetideDrug
Etelcalcetide is provided as a sterile lyophilized powder to be reconstituted with sterile water for injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Serum Corrected Calcium < 7.5 mg/dL During the 4-week Treatment PeriodTime frame: 4 weeks
Locations
40 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Alhambra, California
Research Site
Azusa, California
Research Site
Bakersfield, California
Research Site
Chula Vista, California
Research Site
La Mesa, California
Research Site
Los Angeles, California
Research Site
Lynwood, California
Research Site
Riverside, California
Research Site
Whittier, California
Research Site
Arvada, Colorado
Research Site
North Haven, Connecticut
Research Site
Coral Springs, Florida
Research Site
Hollywood, Florida
Research Site
Miami, Florida
Research Site
Pembroke Pines, Florida
Research Site
Pinecrest, Florida
Research Site
Tampa, Florida
Research Site
Augusta, Georgia
Research Site
Evergreen Park, Illinois
Research Site
Michigan City, Indiana
Research Site
Baton Rouge, Louisiana
Research Site
Lafayette, Louisiana
Research Site
Columbus, Mississippi
Research Site
Gulfport, Mississippi
Research Site
Farmington, Missouri
Research Site
Kansas City, Missouri
Research Site
St Louis, Missouri
Research Site
Portsmouth, New Hampshire
Research Site
Eatontown, New Jersey
Research Site
College Point, New York
Research Site
Oklahoma City, Oklahoma
Research Site
Philadelphia, Pennsylvania
Research Site
Orangeburg, South Carolina
Research Site
Arlington, Texas
Research Site
Greenville, Texas
Research Site
Houston, Texas
Research Site
McAllen, Texas
Research Site
San Antonio, Texas
Research Site
Fairfax, Virginia
Research Site
Hampton, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.